Proactive Investors - Run By Investors For Investors

Collagen Solutions rises as it signs manufacturing agreement for Excellagen wound-healing product

Collagen will manufacture Excellagen for New York-based Olaragen following a deal signed in 2018 between the latter and Gene Biotherapeutics, for whom Collagen originally made the product
Excellagen box and syringe
Excellagen is designed to treat wounds that are complex and difficult to heal such as diabetic foot ulcers

Collagen Solutions PLC (LON:COS) shares moved up in early trading Tuesday after it signed a manufacturing agreement for the Excellagen product with Olaregen Therapeutix, a New York-based firm focused on products in the wound care market.

Under the agreement, AIM-listed Collagen will manufacture Excellagen for Olaregen following a deal signed in September 2018 between the latter and US biotechnology firm Gene Biotherapeutics, for whom Collagen originally made the product and assisted in its development.

READ: Collagen Solutions receives £1.54mln grant from Scottish government

Collagen said that following the agreement between Olaregen and Gene Bio, it was supporting the launch of Excellagen, which is scheduled for the first half of 2019.

Excellagen is designed to treat wounds that are often complex and difficult to heal such as diabetic foot ulcers, burns, and venous (leg) or pressure ulcers among others.

Jamal Rushdy, Collagen’s chief executive, said the new agreement was consistent with the group’s strategy of moving up the value chain by “collaborating with industry partners to develop and launch innovative products”.

Anthony J Dolisi, the chief executive of Olaregen, said the firm had “the utmost confidence” in Collagen, adding that the agreement “may be our most important partnership”.

Shares were up 1.4% at 3.7p.

View full COS profile View Profile

Collagen Solutions PLC Timeline

Related Articles

scientist in laboratory
May 24 2019
Here we take a closer look at healthcare investor NetScientific PLC (LON:NSCI)
dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight
cancer
February 25 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use